Cite
HARVARD Citation
Hanna, M. et al. (2019). Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial. Lancet neurology. 18 (9), pp. 834-844. [Online].